TY - JOUR
T1 - Pregnancy after breast cancer
T2 - Are young patients willing to participate in clinical studies?
AU - Pagani, Olivia
AU - Ruggeri, Monica
AU - Manunta, Silvia
AU - Saunders, Christobel
AU - Peccatori, Fedro
AU - Cardoso, Fatima
AU - Kaufman, Bella
AU - Paluch-Shimon, Shani
AU - Gewefel, Hanan
AU - Gallerani, Elisa
AU - Abulkhair, OMalkahi
AU - Pistilli, Barbara
AU - Warner, Ellen
AU - Saloustros, Emmanouil
AU - Perey, Lucien
AU - Zaman, Khalil
AU - Rabaglio, Manuela
AU - Gelber, Shari
AU - Gelber, Richard D.
AU - Goldhirsch, Aron
AU - Korde, Larissa
AU - Azim, Hatem A.
AU - Partridge, Ann H.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy.
AB - Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy.
KW - Breast cancer
KW - Endocrine treatment
KW - Estrogen receptor
KW - Pregnancy
KW - Young patients
UR - https://www.scopus.com/pages/publications/84936845953
U2 - 10.1016/j.breast.2015.01.005
DO - 10.1016/j.breast.2015.01.005
M3 - Article
C2 - 25662412
AN - SCOPUS:84936845953
SN - 0960-9776
VL - 24
SP - 201
EP - 207
JO - Breast
JF - Breast
IS - 3
ER -